AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](http://www.worldpharmanews.com/images/stories/logo/astrazeneca_b.gif)
Novo Nordisk reaches settlements regarding Oil-for-Food activities
- Details
- Category: Novo Nordisk
![Novo Nordisk Novo Nordisk](http://www.worldpharmanews.com/images/stories/logo/novonordisk_b.gif)
Nycomed files European marketing authorisation application for Daxas®
- Details
- Category: Nycomed
![Nycomed Nycomed](http://www.worldpharmanews.com/images/stories/logo/nycomed.gif)
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline plc (GSK) GlaxoSmithKline plc (GSK)](http://www.worldpharmanews.com/images/stories/logo/gsk.gif)
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
- Details
- Category: Bayer
![The Bayer Group The Bayer Group](http://www.worldpharmanews.com/images/stories/logo/bayer.gif)
Pfizer And Wisconsin Alumni Research Foundation (WARF) Sign License Agreement
- Details
- Category: Pfizer
![Pfizer, Inc Pfizer, Inc](http://www.worldpharmanews.com/images/stories/logo/pfizer_b.gif)
GlaxoSmithKline update: influenza A (H1N1)
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline (GSK) GlaxoSmithKline (GSK)](http://www.worldpharmanews.com/images/stories/logo/gsk.gif)
More Pharma News ...
- Outcome of new Mirapexin®/Sifrol® (pramipexole) study
- Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors
- Pfizer Reports First-Quarter 2009 Results
- Q1/2009: Merck Revenues Remain Stable at € 1.9 Billion
- Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
- Pfizer And University College London Announce Collaboration To Advance Development Of Stem Cell-Base
- Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08